Robert Baffi
Director/Board Member chez MOSAIC IMMUNOENGINEERING, INC.
Fortune : - $ au 31/03/2024
Profil
Robert A.
Baffi is currently serving as the Director at the National Institute for Bioprocessing Research & Training.
He is also currently holding positions as the Director at Neurogene, Inc., the Independent Director at Neurogene, Inc., the Director at Bionic Sight, Inc., the Independent Director at Mosaic ImmunoEngineering, Inc., and the Venture Partner at Samsara Biocapital LLC.
In his former roles, Dr. Baffi worked as the Director at Genentech, Inc. from 1986 to 2000.
He also served as the Director at Humanigen, Inc. from 2014 to 2015.
Additionally, he held the position of Executive Vice President-Technical Operations at BioMarin Pharmaceutical, Inc. from 2000 to 2020.
He also worked as a Research Scientist at Cooper Biomedical, Inc.Dr. Baffi completed his undergraduate, graduate, and doctorate degrees at City University of New York in 1983.
He also obtained an MBA from Regis University in 2001.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/03/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Robert Baffi
| Sociétés | Poste | Début |
|---|---|---|
| MOSAIC IMMUNOENGINEERING, INC. | Director/Board Member | 10/06/2021 |
National Institute for Bioprocessing Research & Training
 National Institute for Bioprocessing Research & Training BiotechnologyHealth Technology The National Institute for Bioprocessing Research & Training (NIBRT) is a center of excellence for training and research in biopharmaceutical manufacturing. NIBRT operates in a world-class facility in Ireland, purpose-built to closely replicate a modern bioprocessing plant with state-of-the-art equipment. NIBRT offers the highest quality training and research solutions to support the growth and development of the biopharma manufacturing industry. | Director/Board Member | - |
Neurogene, Inc.
 Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | Director/Board Member | 17/09/2020 |
Samsara Biocapital LLC
 Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | Private Equity Investor | 01/03/2021 |
Anciens postes connus de Robert Baffi
| Sociétés | Poste | Fin |
|---|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Corporate Officer/Principal | 04/05/2020 |
| HUMANIGEN, INC. | Director/Board Member | 20/11/2015 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Director/Board Member | 01/01/2000 |
Cooper Biomedical, Inc.
 Cooper Biomedical, Inc. Medical SpecialtiesHealth Technology Cooper Biomedical, Inc. manufactures and sells medical devices. The private company is based in Malvern, PA. | Corporate Officer/Principal | - |
Formation de Robert Baffi
| City University of New York | Doctorate Degree |
| Regis University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| HUMANIGEN, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
National Institute for Bioprocessing Research & Training
National Institute for Bioprocessing Research & Training BiotechnologyHealth Technology The National Institute for Bioprocessing Research & Training (NIBRT) is a center of excellence for training and research in biopharmaceutical manufacturing. NIBRT operates in a world-class facility in Ireland, purpose-built to closely replicate a modern bioprocessing plant with state-of-the-art equipment. NIBRT offers the highest quality training and research solutions to support the growth and development of the biopharma manufacturing industry. | Health Technology |
Cooper Biomedical, Inc.
Cooper Biomedical, Inc. Medical SpecialtiesHealth Technology Cooper Biomedical, Inc. manufactures and sells medical devices. The private company is based in Malvern, PA. | Health Technology |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | Finance |
Neurogene, Inc.
Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | Health Technology |
| Mosaic ImmunoEngineering, Inc. |
